Fermented lactobacillus mucus strain A21038 with anti-oxidation, anti-aging and anti-tumor activity and application of fermented lactobacillus mucus strain A21038
By developing Lactobacillus fermented Lactobacillus mucin strain A21038, the problem that the existing Lactobacillus has not yet possessed antioxidant, anti-aging and anti-tumor activities was solved, and effective inhibition of DPPH free radicals, H2O2 and tumor cells was achieved, demonstrating significant health Benefits, providing efficient solutions for a variety of health products.
Patent Information
- Application Number
- CN202411147058.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-20
AI Technical Summary
The existing Lactobacillus strains have not yet possessed antioxidant, anti-aging and anti-tumor activities at the same time, and cannot effectively take into account these three health benefits.
A novel Lactobacillus fermented mucinous strain A21038 was developed to verify its antioxidant, anti-aging and anti-tumor activities under in vitro conditions, including the scavenging of DPPH radicals, hydroxyl radicals, superoxide anions and H2O2 , and superoxide dismutase and glutathione peroxidase activities, significantly inhibit the proliferation of colon cancer and melanoma cells.
Lactobacillus fermented mucinous strain A21038 demonstrated more than 98% of DPPH free radical clearance, good H2O2 tolerance, significant anti-aging effect and inhibitory ability of a variety of tumor cells, proving that it has antioxidant, anti-aging and anti-aging. Tumor activity has high application value for the preparation of anti-tumor drugs, antibacterial drugs and anti-aging products.
Smart Images

Figure CN119015203A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of functional microorganisms, and specifically relates to a fermented mucus lactobacillus (Limosilactobacillusfermentum) strain A21038 with anti-oxidation, anti-aging and anti-tumor activities and an application thereof. Background Art
[0002] Intestinal microorganisms have played an important role in people's lives. They can not only maintain intestinal health, but also regulate various signal pathways through metabolites, and are closely related to the occurrence and treatment of various diseases. For example, lactobacillus that coexists with the human intestine is a beneficial bacteria that inhibits the invasion of pathogens, relieves intestinal inflammation and damage, delays aging, and even plays an important role in resisting the development of tumors. Fermented mucus lactobacillus is a type of probiotic approved by the Ministry of Health that can be used for food. It can colonize in the human intestine, change the host flora composition and have a beneficial effect on the host. Adding some active probiotics in time to the diet is extremely important for people who show related symptoms or diseases. For example, publication number CN113234612A discloses a fermented lactobacillus ZS40 with a preventive effect on colitis. The strain can better relieve inflammation by inhibiting the activation of NF-κB and MAPK signaling pathways.
[0003] Redox reactions are taking place in the human body all the time. The skin is the first barrier of the human body, and aging damage is inevitable. The patent with publication number CN117363524A discloses a strain of Lactobacillus gasseri MY4 and its application in the preparation of sleep-aiding and whitening food and medicine. The strain has the effects of anti-oxidation, whitening and anti-aging. In addition, the research of Luo et al. reported a strain of Lactobacillus mucosa FLRE5K1 strain. The experimental results showed that it can significantly reduce the number of melanoma cells in mice, and has no toxic side effects on non-cancerous tissues, and has anti-melanoma activity. It can be seen that lactobacillus is widely used as a probiotic in anti-oxidation and anti-tumor. However, there is no report on lactobacillus with both anti-oxidation, anti-aging and anti-tumor activities. Summary of the invention
[0004] In view of this, the object of the present invention is to provide an application of fermented mucus lactobacillus in the preparation of antioxidant, anti-aging and anti-tumor products.
[0005] The present invention also aims to provide a novel Limosilactobacillusfermentum strain A21038, which has antioxidant, anti-aging and anti-tumor activities.
[0006] The invention provides the use of fermented mucus lactobacillus (Limosilactobacillusfermentum) in preparing products having at least two of the following functions: anti-oxidation, anti-aging, antibacterial and anti-tumor.
[0007] Preferably, the antioxidant is manifested in the ability to scavenge at least one of the following: DPPH free radicals, hydroxyl free radicals, superoxide anions and H2O2.
[0008] Preferably, the anti-aging effect is manifested in superoxide dismutase activity and / or glutathione peroxidase activity.
[0009] Preferably, when preparing an antioxidant and / or anti-aging product, the product comprises at least one of the following: medicine, health care product, cosmetic and food.
[0010] Preferably, the antibacterial bacteria include Escherichia coli.
[0011] Preferably, the tumor or cancer in the anti-tumor agent includes colon cancer and / or melanoma.
[0012] Preferably, when preparing the antibacterial and / or anti-tumor product, the product comprises a medicine.
[0013] The invention provides a fermented mucus lactobacillus strain A21038, whose preservation number is GDMCC No: 64675.
[0014] The invention provides a probiotic, wherein the active ingredient comprises the fermented mucus lactobacillus strain A21038.
[0015] The present invention provides the use of the fermented mucus lactobacillus strain A21038 or the probiotic in preparing a product having at least one of antioxidant, anti-aging, antibacterial and anti-tumor properties.
[0016] The present invention provides the use of fermented mucus lactobacillus (Limosilactobacillusfermentum) in the preparation of products with at least two functions: anti-oxidation, anti-aging, antibacterial and anti-tumor. The present invention uses fermented mucus lactobacillus strains to carry out experiments on antioxidant, anti-aging, antibacterial and anti-tumor properties under in vitro conditions. The fermented mucus lactobacillus strain has good inhibitory ability against pathogenic bacteria Escherichia coli and / or Escherichia coli, indicating that the fermented mucus lactobacillus strain has good antibacterial properties. The present invention uses DPPH free radicals, hydroxyl free radicals (OH -) and superoxide anion and hydrogen peroxide (H2O2) as indicators to illustrate the antioxidant properties. The results show that the fermented mucus lactobacillus has a scavenging rate of more than 98% for DPPH free radicals, and can still grow after being cultured in 0.5mM high concentration H2O2 for 12h, indicating that it has good tolerance to H2O2 and can play an antioxidant role. In terms of anti-aging, the results show that the fermented mucus lactobacillus has superoxide dismutase (SOD) activity and glutathione peroxidase (GSH-Px) activity, and the effect of delaying skin aging is comparable to that of the commercial strain Lactobacillus rhamnosus LGG. At the same time, human colon cancer cells HCT116 and mouse colon cancer cells MC38 were used as experimental subjects to verify the anti-tumor effect of the fermented mucus lactobacillus. The results show that both live bacteria and inactivated bacteria have the performance of inhibiting the proliferation of colon cancer cells, and the inhibitory effect is correlated with time. At the same time, mouse melanoma cells B16 were used as experimental subjects to verify the anti-tumor effect of the fermented mucus lactobacillus, and the results were the same as the colon cancer inhibition results, and it also had the effect of inhibiting the growth of melanoma. Therefore, the present invention proves for the first time that fermented mucus lactobacillus has antioxidant, anti-aging, antibacterial and anti-tumor activities at the same time, and has extremely high application value in the preparation of anti-tumor drugs, antibacterial drugs, anti-aging and / or antioxidant drugs, health products and cosmetics.
[0017] The present invention also provides a fermented mucus lactobacillus strain A21038, with a deposit number of GDMCC No: 64675. The strain A21038 was isolated from a sample of intestinal feces from a healthy centenarian, and was identified as a fermented mucus lactobacillus by morphological and molecular identification. The strain A21038 has a fast growth rate, is resistant to gastrointestinal fluid and ox bile salts, and can colonize the intestine through the gastrointestinal tract to exert its effect. The strain A21038 has a good inhibitory effect on pathogenic Escherichia coli, and at the same time has the ability to scavenge free radicals, is tolerant to high concentrations of hydrogen peroxide, and has good antioxidant capacity. In addition, the strain A21038 has superoxide dismutase (SOD) activity and glutathione peroxidase (GSH-Px) activity, and has the ability to delay aging. In addition, both the live bacteria or inactivated bacteria of the strain A21038 have an inhibitory effect on the cell proliferation of colon cancer and melanoma. It can be seen that the strain A21038 has antioxidant, anti-aging, antibacterial and anti-tumor properties, and has extremely high application value in industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The morphological diagram of the fermentative Lactobacillus mucilaginosus strain A21038;
[0019] Figure 2 It is the growth curve of fermentation Lactobacillus mucilaginosus strain A21038;
[0020] Figure 3 This is a graph showing the test results of the tolerance of the fermented Lactobacillus mucilaginosus strain A21038 to artificial gastrointestinal fluid;
[0021] Figure 4 This is a graph showing the test results of the tolerance of fermented Lactobacillus mucilaginosus strain A21038 to bovine bile salts;
[0022] Figure 5 This is a graph showing the test results of the tolerance of fermented Lactobacillus mucilaginosus strain A21038 to H2O2;
[0023] Figure 6 This is the result of the test on the inhibition of the growth of human colon cancer cell HCT116 by fermented Lactobacillus mucilaginosus strain A21038;
[0024] Figure 7 This is the result of the test on the inhibition of the growth of mouse colon cancer cell MC38 by fermented Lactobacillus mucilaginosus strain A21038;
[0025] Figure 8 This is the result of the test on the inhibition of the growth of mouse melanoma cells B16 by fermented Lactobacillus mucinus strain A21038.
[0026] Biomaterial Deposit Information
[0027] Limosilactobacillusfermentum strain A21038 was deposited in Guangdong Provincial Microbiological Culture Collection Center on May 23, 2024, with the abbreviation of GDMCC, and the address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the deposit number is GDMCC No: 64675. DETAILED DESCRIPTION
[0028] The invention provides the use of fermented mucus lactobacillus in preparing a product having at least two of the following functions: anti-oxidation, anti-aging, antibacterial and anti-tumor.
[0029] In the present invention, the fermented mucus lactobacillus preferably includes a cell and / or a spore. The fermented mucus lactobacillus cell refers to a solid-phase cell obtained by enlarging and culturing the activated fermented mucus lactobacillus, separating the solid and the liquid, and collecting the solid-phase cell. The plant lactobacillus spore refers to a round or oval stress-resistant dormant body formed in the cell of the fermented mucus lactobacillus after the fermented mucus lactobacillus grows and develops to a certain stage.
[0030] In the present invention, the existence form of the fermented mucus lactobacillus preferably includes at least one of the following: a culture solution of the fermented mucus lactobacillus, a culture supernatant of the fermented mucus lactobacillus and a bacterial suspension of the fermented mucus lactobacillus. The method for preparing the culture solution of the fermented mucus lactobacillus preferably inoculates the activated fermented mucus lactobacillus into an MRS liquid culture medium for culture to obtain a culture solution. The culture temperature is preferably 36 to 38°C, more preferably 37°C. The culture time is 12 to 16h, more preferably 14h. The inoculation amount of the fermented mucus lactobacillus is preferably 5% to 10%, more preferably 8%. The method for preparing the culture supernatant of the fermented mucus lactobacillus and the bacterial suspension of the fermented mucus lactobacillus preferably separates the culture solution prepared above into solid and liquid, the liquid phase is the culture supernatant, and the solid phase is collected and resuspended to obtain a bacterial suspension.
[0031] In the present invention, the fermentation of Lactobacillus mucilaginosus strain preferably includes the fermentation of Lactobacillus mucilaginosus strain A21038. The fermentation of Lactobacillus mucilaginosus strain A21038 has a deposit number of GDMCC No: 64675.
[0032] In the present invention, when preparing a product comprising two functions, the application preferably includes the application in preparing antioxidant and anti-aging products and / or the application in preparing antibacterial and anti-tumor products; or the application in preparing antioxidant and anti-tumor products and / or the application in preparing antibacterial and anti-aging products; or the application in preparing anti-aging and anti-tumor products and / or the application in preparing antioxidant and antibacterial products.
[0033] In the present invention, when preparing a product with three functions, the application preferably includes the application in preparing a product with antioxidant, anti-aging and antibacterial properties; or the application in preparing a product with antioxidant, antibacterial and anti-tumor properties; or the application in preparing a product with anti-aging, antibacterial and anti-tumor properties; or the application in preparing a product with antioxidant, anti-aging and anti-tumor properties. When preparing a product with four functions, the application preferably includes the application in preparing a product with antioxidant, anti-aging, antibacterial and anti-tumor properties.
[0034] In the present invention, the antioxidant is preferably manifested in the ability to scavenge at least one of the following: DPPH free radicals, hydroxyl free radicals, superoxide anions and H2O2, more preferably DPPH free radicals and H2O2. The anti-aging is preferably manifested in having superoxide dismutase activity and / or glutathione peroxidase activity. When preparing antioxidant and / or anti-aging products, the products preferably include at least one of the following: medicines, health products, cosmetics and foods. The bacteria in the antibacterial property preferably include Escherichia coli. The tumor or cancer in the anti-tumor property preferably includes colon cancer and / or melanoma. When preparing the antibacterial and / or anti-tumor products, the products preferably include medicines. When preparing the antibacterial products, the products can also prepare antibacterial agents used under in vitro conditions. The present invention has no special restrictions on the method for preparing the products with the above functions, and the products can be prepared by methods well known in the art, for example, the culture solution, supernatant or fermentation solution of fermented mucus lactobacillus is used as an active ingredient and mixed with excipients to prepare various forms of products.
[0035] The invention provides a fermented mucus lactobacillus strain A21038, whose preservation number is GDMCC No: 64675.
[0036] In the present invention, the strain A21038 is isolated from the intestinal feces sample of a healthy centenarian. The colonies of the strain A21038 on the MRS plate are round, with neat edges, opaque, raised in the middle, smooth surface, light yellow, and belong to Gram-positive bacteria. The nucleotide sequence of the 16S rDNA of the strain A21038 is shown in SEQ ID NO: 1. Through morphological identification and molecular identification, the strain A21038 belongs to fermented mucus lactobacillus. Through the growth curve of the strain A21038, it was found that the strain A21038 has the characteristics of fast growth rate, entering the logarithmic phase in 2h, 6 to 24h is the stable phase, and no decay phase occurs within 24h.
[0037] In the present invention, the strain A21038 was treated in artificial gastric juice for 3 hours, and the survival rate was 100%. It was treated in artificial intestinal juice for 7 hours, and the survival rate was maintained at more than 70%, which was better than the control strain A20014 screened in the same batch. The survival rate of the strain A21038 was 100% when it was treated in 0.5g / L ox bile salt for 24 hours. The above results show that the strain A21038 has the ability to resist gastrointestinal juice and ox bile salt, and can colonize the intestinal tract to exert its effect.
[0038] In the present invention, the strain A21038 has a good inhibitory effect on Escherichia coli pathogenic bacteria. The Escherichia coli pathogenic bacteria preferably include Escherichia coli and / or Escherichia coli. In the embodiment of the present invention, Escherichia coli strain O157:H7 (ATCC 35150) and Escherichia coli (ATCC 25922) are used as representatives of pathogenic bacteria to illustrate the antibacterial properties of the strain A21038. The results show that the inhibition zone of the strain A21038 on the Escherichia coli strain O157:H7 is 21.33mm, and the antibacterial effect is better than the control strain A20014 screened in the same batch; the inhibition zone of the strain A21038 on the Escherichia coli strain is 25.00mm, and the antibacterial effect is equivalent to the control strain A20014 screened in the same batch.
[0039] In the present invention, the strain A21038 has good free radical scavenging ability, is tolerant to high concentrations of hydrogen peroxide, and has good antioxidant capacity. The free radicals preferably include DPPH free radicals, hydroxyl free radicals (OH - ) and superoxide anion (O2 - ). The DPPH free radical is a very stable nitrogen-centered free radical, which is one of the important indicators of the antioxidant capacity of the sample and is widely used in the research of antioxidant foods, health products and medicines. Hydroxyl free radical (OH-) is a kind of reactive oxygen. Hydroxyl free radical can kill red blood cells, degrade DNA, cell membranes and polysaccharide compounds. Then it was found that many harmful effects caused by it were significantly reduced when scavengers of hydroxyl free radicals were added. Superoxide anion is also a detection index of antioxidant activity. When an organism is subjected to external stress, reactive oxygen such as superoxide anion in the organism is produced and accumulated in large quantities, which can be used as a signal of oxidative stress in the organism. Therefore, the generation of superoxide anion free radicals in an organism under adverse conditions can indirectly reflect the damage status of tissue cells and the strength of resistance. Hydrogen peroxide (H2O2) is the most common reactive oxygen molecule in an organism and a byproduct of reactive oxygen metabolism. It is mainly produced by superoxide dismutase (SOD) and xanthine oxidase (XOD), and is catalyzed and degraded by catalase (CAT) and active enzyme (POD). The concentration of H2O2 in a normal human body is at a low level, generally 10 to 100 μM. High concentrations of H2O2 will induce an increase in oxidative stress in the body, directly or indirectly oxidize biological macromolecules such as nucleic acids and proteins in cells, and damage cell membranes, thereby accelerating cell aging and disintegration, producing toxic effects on human cells, and even causing cell dysfunction and organ damage, leading to the occurrence of related diseases.
[0040] In one embodiment of the present invention, the strain A21038 has a DPPH scavenging rate of more than 98%, which is significantly better than the control strain A20014 (15%). The strain A21038 has a hydroxyl radical scavenging rate of 20%, which is significantly better than the control strain A20014 (10%). The strain A21038 has a superoxide anion scavenging rate of 33%, which is significantly better than the control strain A20014 (24%). In another embodiment of the present invention, the strain A21038 was measured for its tolerance to high concentrations of hydrogen peroxide. The strain A21038 can still grow after being treated in 0.5mM H2O2 for 12h, and has a good tolerance to H2O2, while the control strain A20014 cannot reproduce under the same conditions and has no tolerance to H2O2.
[0041] In the present invention, the strain A21038 has superoxide dismutase activity and glutathione peroxidase (GSH-Px) activity, and has the ability to delay aging. Superoxide dismutase can catalyze the dismutation of superoxide anions to generate hydrogen peroxide (H2O2) and oxygen (O2). It is an important antioxidant enzyme in the body and plays a role in preventing skin aging and damage. Glutathione peroxidase specifically uses glutathione (GSH) to reduce peroxides, especially hydrogen peroxide. The glutathione is composed of glutamic acid, cysteine and glycine, and has antioxidant and integrated detoxification effects. Glutathione is not only used in medical drugs, it also has the whitening effect of reducing melanin growth and delaying aging. In one embodiment of the present invention, it is proved that the strain A21038 has the ability to secrete superoxide dismutase and glutathione peroxidase. The activity of superoxide dismutase was measured to be 0.27U / 10 4 CFU, and the activity of glutathione peroxidase was 0.77 nmol / min / mL.
[0042] In the present invention, both live and inactivated bacteria of the strain A21038 have an inhibitory effect on the cell proliferation of colon cancer and melanoma. The preparation method of the inactivated bacteria of the strain A21038 is preferably to treat the bacteria at 70°C for 30 minutes. In one embodiment of the present invention, the live bacteria of the strain A21038 are superior to the inactivated bacteria in inhibiting the growth of tumor cells, and the same result exists in the commercial strain LGG.
[0043] The invention provides a probiotic, wherein the active ingredient comprises the fermented mucus lactobacillus strain A21038.
[0044] In the present invention, the probiotic agent refers to supplementing the beneficial bacteria in the intestine so that the beneficial bacteria have sufficient quantity and exert unique biological effects, thereby achieving the purpose of health care or disease prevention and treatment. The live bacteria concentration of the fermented Lactobacillus mucosa strain A21038 is preferably 1×10 9 CFU / mg~1×10 11 CFU / mg or 1×10 9 CFU / mL~1×10 11 CFU / mL, more preferably 5×10 9 CFU / mg~5×10 10 CFU / mg or 5×10 9 CFU / mL~5×10 10 CFU / mL, more preferably 8×10 9 CFU / mg~2×10 11 CFU / mg or 8×10 9 CFU / mL~2×10 11 CFU / mL, the most preferred is 1×10 10 CFU / mg or 1×10 10 CFU / mL. The dosage form of the probiotic is preferably at least one of the following: tablets, drops, capsules and powders. The powder is processed by low-temperature freeze-drying technology to ensure the activity of the probiotics. The auxiliary materials of the powder preferably include freeze-drying agents, such as skimmed milk powder, etc. The powder is suitable for warm water and is suitable for infants. The tablet is prepared by mixing the fermented mucus Lactobacillus strain A21038 and auxiliary materials and pressing them into tablets, which are suitable for chewing and taking. The auxiliary materials preferably include sweeteners or cocoa powder, etc. The capsule is preferably the fermented mucus Lactobacillus strain A21038 alone or mixed with auxiliary materials as the capsule core in the capsule shell. The drops are made by mixing the fermented mucus Lactobacillus strain A21038 with edible oil to make drops that are isolated from air and moisture. When taking, open the dropper port to squeeze the encapsulated oil into the mouth.
[0045] In view of the multiple functions of the fermented Lactobacillus mucoides strain A21038, the present invention provides a use of the fermented Lactobacillus mucoides strain A21038 or the probiotic in the preparation of a product having at least one of antioxidant, anti-aging, antibacterial and anti-tumor properties.
[0046] The present invention does not impose any particular limitation on the specific type of the product, and any product type with specific efficacy known in the art may be used.
[0047] The fermented Lactobacillus mucosa strain A21038 with antioxidant, anti-aging and anti-tumor activities and its application provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0048] Example 1
[0049] Isolation and identification of Lactobacillus mucilaginosus strain A21038
[0050] The intestinal fecal samples of healthy centenarians were diluted in multiples, spread on MRS plates, and cultured in a biochemical incubator at 37°C for 48 hours to obtain single colonies. Pick a single colony, inoculate it in MRS liquid culture medium, and culture it in a 37°C shaker for 12 to 16 hours. Take the bacterial liquid and streak it on the MRS plate, and continue to culture a single colony. After 24 hours of culture, pick a single colony and streak it again, and continue to culture a single colony, which is the pure isolated lactobacillus. Pick a single colony of pure isolated lactobacillus, perform Gram staining, 16SrDNA PCR amplification, and 16SrDNA sequencing, and compare the results with the NCBI database.
[0051] The growth state of the strain A21038 in the MRS plate is as follows Figure 1 As shown, the colonies are round, with neat edges, opaque, convex in the middle, smooth surface, and light yellow color, and are Gram-positive bacteria.
[0052]
[0053] Example 2
[0054] Growth curve of Lactobacillus mucilaginosus strain A21038
[0055] The strain was taken out from the glycerol storage tube, streaked on an MRS solid plate, and cultured in a 37°C incubator. After 24 hours, a single clone was picked out and cultured in 2 ml of MRS liquid culture medium for 12 to 16 hours. This step was repeated once to fully activate the strain. Then 0.2 mL of the bacterial suspension was pipetted into a 96-well plate, and three replicate wells were made. The growth within 24 hours was detected using an ELISA reader with a detection wavelength of 600 nm. Statistics were performed and graphs were drawn after the determination.
[0056] Figure 2 The growth curve of fermentation Lactobacillus mucilaginosus A21038 is shown. The strain A21038 grows fast, enters the logarithmic growth phase after 2 hours, and the stable phase is 6-24 hours. The bacteria grows stably and does not show a decay phase within 24 hours.
[0057] Example 3
[0058] Resistance of Lactobacillus mucilaginosus strain A21038 to artificial gastrointestinal fluid
[0059] After thawing, the strain A21038 and the other strain fermentation mucus lactobacillus A20014 (as a control strain) separated from the feces of centenarians were streaked on MRS solid culture medium, placed in a 37°C incubator for overnight culture, and after 24 hours, single clones were picked and inoculated into MRS liquid culture medium, and cultured in a shaking table at 37°C for 12 to 16 hours. This step was repeated once to fully activate the strains and obtain a bacterial solution. The bacterial liquid was inoculated into artificial gastric juice of pH 2.5 (the formula was 10 g of pepsin, 16.4 ml of hydrochloric acid, and the volume was adjusted to 100 ml with distilled water) at an inoculum size of 10%, and 100 μl of each was applied to an MRS plate at three time points (0 h, 1 h, and 3 h). After culturing in a biochemical incubator at 37° C. for 48 h, the number of single colonies was counted. The bacterial liquid treated with artificial gastric juice for 3 h was inoculated into artificial intestinal juice of pH 6.8 (the formula was 10 g of pancreatic enzyme, 6.8 g of potassium dihydrogen phosphate, and the volume was adjusted to 1000 ml with distilled water, and the pH value was adjusted with NaOH) at an inoculum size of 10%, and 100 μl of each was applied to an MRS plate at four time points (0 h, 2 h, 4 h, and 8 h). After culturing in a biochemical incubator at 37° C. for 48 h, the number of single colonies was counted, and the survival rate was calculated according to Formula I.
[0060] Survival rate (%) = (number of single colonies at different time points / number of single colonies at 0 h) × 100% Formula I
[0061] The results are as follows Figure 3The results showed that the survival rate of the control strain A20014 in artificial gastric juice at pH 2.5 reached 100%, while its survival rate in intestinal juice decreased with time, and the survival rate was less than 20% at 7 hours in intestinal juice. Compared with the control strain A20014, the survival rate of the strain A21038 reached 100% at 3 hours in artificial gastric juice, and the survival rate was still above 70% after 7 hours in intestinal juice, which was significantly better than the control strain A20014. This shows that the strain A21038 has excellent gastrointestinal tolerance and can smoothly pass through the stimulation of gastrointestinal juice to reach the intestine to exert its effect.
[0062] Example 4
[0063] Determination of the tolerance of lactobacillus mucilaginosus A21038 to ox bile salts
[0064] After thawing the glycerol storage tubes of the strain A21038 and other strains of fermented mucus lactobacillus A20014 isolated from the feces of centenarians (as a control strain), they were streaked with MRS solid culture medium and placed in a 37°C incubator for overnight culture. After 24 hours, single clone colonies were picked and inoculated into MRS liquid culture medium and cultured in a 37°C shaker for 12 to 16 hours. Repeat this step once to fully activate the strain and obtain a bacterial solution. Take 1 mL respectively and add it to MRS culture medium containing 0.3g / L or 0.5g / L ox bile salt, respectively, and culture anaerobically at 37°C for 18 hours. Take 100uL of the culture solution at 0h, 2h, and 24h after addition for gradient dilution and coating, place it under anaerobic conditions at 37°C for 1-2 days, and count the number of live bacteria. Calculate the bile salt tolerance survival rate of the strain according to Formula II:
[0065] Bile salt tolerance survival rate = (N h viable bacteria count / 0 h viable bacteria count) × 100% Formula II
[0066] Wherein, N represents 2h or 24h.
[0067] The results are as follows Figure 4 As shown, compared with the control strain A20014, the survival rate of the strain A21038 was still over 100% after 24 hours in the presence of 0.5 g / L ox bile salt, indicating that the strain A21038 has an excellent bile salt tolerance ability.
[0068] Example 5
[0069] Fermented Lactobacillus mucilaginosus strain A21038 inhibits pathogenic bacteria function
[0070] will be in the logarithmic growth phase (concentration 1×10 9 0.1 mL of pathogenic bacteria Escherichia coli O157:H7 (ATCC35150) and Escherichia coli (ATCC 25922) with a concentration of CFU / mL was aspirated and spread on an LB plate, and an Oxford cup was placed.
[0071] According to the method for activating the strain in Example 2, the activated bacterial suspension was obtained and the OD 600 Adjust to 0.5 (concentration is 1×10 6 CFU / mL), take 200μl of bacterial suspension and inoculate it into Oxford cup, do 3 replicates, overnight, and observe its effect on pathogenic bacteria. The size of the inhibition zone is measured by a ruler, and the average value of 3 replicates is taken. The results are shown in Table 1 below.
[0072] Table 1 Results of strain inhibition of pathogens
[0073]
[0074] The results showed that the fermented Lactobacillus mucilaginosus strain A21038 had the ability to significantly inhibit the growth of pathogenic bacteria and was superior to the control strain A20014.
[0075] Example 6
[0076] Antioxidant function of fermented Lactobacillus mucilaginosus strain A21038
[0077] According to the method of activating strain A21038 in Example 2, the activated bacterial suspension and the control strain A20014 bacterial suspension were obtained, and the bacterial suspension was adjusted to OD 600 to 0.5 (concentration is 1×10 6 CFU / mL) for later use.
[0078] When antioxidants are present, DPPH free radicals are scavenged, the solution color becomes lighter, and the absorbance at 515nm decreases. Within a certain range, the change in absorbance is proportional to the degree of free radical scavenging. The degree of absorbance decrease reflects the ability of the sample to scavenge DPPH free radicals. The two strains were tested according to the instructions of the DPPH free radical scavenging ability kit (Jianglai Biology).
[0079] 2-Deoxyribose in hydroxyl radical (OH - ) is oxidized to a malondialdehyde analogue in the presence of thiobarbituric acid (TBA), and then condenses with thiobarbituric acid (TBA) to form a colored product. The maximum absorption peak of the colored product at 532 nm is measured, and the hydroxyl radical (OH - ) content. According to the hydroxyl radical (OH - ) content determination kit (Jianglai Biological) instructions were used to detect the two strains.
[0080] Superoxide anion (O2 - ) reacts with hydroxylamine to produce NO2 - , NO2 -Under the action of p-aminobenzenesulfonic acid and α-naphthylamine, a pink azo dye is generated. The dye has a maximum light absorption at 540nm. The O2 in the sample can be calculated based on the A540 value. - According to the content of superoxide anion (O2 - ) kit (Greith Biotech) instructions were used to test the two strains.
[0081] The test results are shown in Table 2.
[0082] Table 2 Antioxidant test results of two strains
[0083]
[0084] The results showed that the fermented Lactobacillus mucilaginosus strain A21038 had good antioxidant capacity and was significantly better than the control strain A20014.
[0085] Example 7
[0086] Determination of the tolerance of Lactobacillus mucilaginosus strain A21038 to H2O2
[0087] Hydrogen peroxide (H2O2) is the most common reactive oxygen molecule in the body and a byproduct of reactive oxygen metabolism. It is mainly produced by catalysis such as SOD and XOD, and degraded by catalysis such as CAT and POD. The concentration of H2O2 in a normal human body is at a low level, generally 10 to 100 μM. High concentrations of H2O2 will induce an increase in oxidative stress in the body, directly or indirectly oxidize biological macromolecules such as nucleic acids and proteins in cells, and damage cell membranes, thereby accelerating cell aging and disintegration, producing toxic effects on human cells, and even causing cell dysfunction and organ damage, leading to the occurrence of related diseases.
[0088] The strain A21038 and the control strain A20014 were taken out from the glycerol storage tube and activated by streaking three times, and a single clone was picked out and cultured in MRS liquid culture medium. Different concentrations of H2O2, such as 0.5mM, 1.0mM, and 2.0mM, were added and the growth was detected using an ELISA instrument. After the determination, a plot was drawn.
[0089] The results are as follows Figure 5 As shown, fermentation of Lactobacillus mucilaginosus A21038 ( Figure 5 A) can still grow in a high concentration of 0.5mM H2O2 for 12h, showing good tolerance to H2O2, while the control strain A20014 cannot reproduce under the same conditions ( Figure 5 B), and has no tolerance to H2O2. This indicates that the strain A21038 can still grow stably under a highly oxidative stress environment in vivo and exert an antioxidant effect.
[0090] Example 8
[0091] Anti-aging function of fermented Lactobacillus mucilaginosus strain A21038
[0092] Superoxide dismutase (SOD) can catalyze the dismutation of superoxide anions to generate hydrogen peroxide (H2O2) and oxygen (O2). It is an important antioxidant enzyme in the body and plays a role in preventing skin aging and damage. Glutathione (GSH) is composed of glutamic acid, cysteine and glycine, and has antioxidant and integrated detoxification effects. Glutathione is not only used in medical drugs, it also has the whitening effect of reducing the growth of melanin and delaying aging.
[0093] The commercial strain Lactobacillus rhamnosus LGG is a beneficial bacteria in the human intestine, which can enhance the body's immunity, improve gastrointestinal function and delay the aging process of the body. According to the results of the above examples, the various properties of the strain A21038 of the present invention are significantly better than the control strain A20014 of the same genus. Therefore, LGG is selected as the control strain in the following examples to study the anti-aging function of the strain A21038 of the present invention.
[0094] (1) Strain A21038 has superoxide dismutase (SOD) activity detection
[0095] The concentrations of the strain A21038 and the commercial strain Lactobacillus rhamnosus LGG were adjusted to 5×10 6 CFU / mL, centrifuge and discard the supernatant, and determine the SOD activity of the strain according to the operating procedures of the SOD activity detection kit (Jianglai Biotechnology). The result is defined as 10 4 When the SOD inhibition rate of a single CFU colony in the reaction system reaches 50%, the corresponding SOD amount is one SOD activity unit.
[0096] (2) Glutathione peroxidase (GSH-Px) activity detection of strain A21038
[0097] The bacterial concentrations of the strain A21038 and the control strain LGG were adjusted to 5×10 6 CFU / mL, centrifuge and discard the supernatant, and determine the GSH-Px content in the strain according to the operating procedures of the GSH-Px detection kit (provided by Gres Biotech). The result is defined as the number of CFU / mL per 10 4 One unit of enzyme activity is when one cell oxidizes 1 nmol of GSH per minute.
[0098] The enzyme activities contained in the fermented Lactobacillus mucilaginosus A21038 are shown in Table 3 below.
[0099] Table 3 Enzyme activity test results
[0100] strain <![CDATA[SOD activity (U / 10 4 CFU)]]> GSH-Px enzyme activity (nmol / min / mL) A21038 0.27 0.77 LGG 0.51 0.77
[0101] The results showed that the fermented Lactobacillus mucilaginosus strain A21038 had good glutathione peroxidase activity and could play a role in delaying skin aging, and its effect was comparable to that of the control strain LGG.
[0102] Example 9
[0103] Inhibitory effect of fermented Lactobacillus mucilaginosus strain A21038 on human colon cancer cells HCT116
[0104] HCT116 cell line was inoculated and cultured in RPMI1640 medium (TransGen) containing 10% fetal bovine serum. When the cells grew to the logarithmic phase, they were digested with trypsin and counted using a hemocytometer. The cells were evenly inoculated in a 96-well plate at 5,000 cells per well and cultured in a 37°C tri-gas incubator overnight.
[0105] The prior art reports that the commercial strain Lactobacillus rhamnosus LGG has anti-tumor effects, so the LGG strain was selected as the positive control of this example. The strain A21038 and the control strain LGG were taken out from the glycerol storage tube, streaked on an MRS solid plate, and placed in a 37°C incubator for culture. After 24 hours, a single clone was picked and cultured in 2 ml of MRS liquid culture medium for 12 to 16 hours. This step was repeated once to fully activate the strain, obtain a bacterial suspension, and adjust the OD of the bacterial suspension. 600 =0.5, concentration is 1×10 6 CFU / mL, after washing with PBS three times, it was divided into live bacteria and inactivated bacteria (70℃30min), and 0.2mL of bacterial suspension was added to each well of a 96-well plate, live bacteria were incubated with cells for 2h, and inactivated bacteria were incubated with cells for 72h after inactivation. CCK-8 reagent (Solerbo) was used to detect the proliferation of HCT116 cells.
[0106] The results are as follows Figure 6 As shown. The live bacteria of the strain A21038 can significantly inhibit the proliferation of HCT116 cells (P<0.0001), and its effect is comparable to that of the control strain LGG. The strain A21038 showed a significant inhibitory effect within 48 hours after inactivation (P<0.001), and was superior to the control strain LGG. The effect of the inactivated strain was significantly weaker than that of the live bacteria. The reason why the inactivated strain can exert a potential anti-tumor cell growth effect may be because the inactivated bacterial protein plays a role, which needs further study.
[0107] Example 10
[0108] Inhibitory effect of fermented Lactobacillus mucilaginosus strain A21038 on mouse colon cancer cells MC38
[0109] MC38 cell line was inoculated and cultured in DMEM medium (TransGen) containing 10% fetal bovine serum. When the cells grew to the logarithmic phase, they were digested with trypsin and counted using a hemocytometer. The cells were evenly inoculated in a 96-well plate at 5,000 cells per well and cultured in a 37°C tri-gas incubator overnight.
[0110] The strain A21038 and the control strain LGG were taken out from the glycerol storage tube, streaked on the MRS solid plate, and cultured in a 37°C incubator. After 24 hours, a single clone was picked and cultured in 2 ml MRS liquid culture medium for 12-16 hours. This step was repeated once to fully activate the strain and obtain a bacterial suspension. The OD of the bacterial suspension was adjusted. 600 =0.5, concentration is 1×10 6 CFU / mL, after washing with PBS three times, the cells were divided into live and inactivated bacteria (70°C for 30 min), and 0.2 mL of bacterial suspension was added to each well of a 96-well plate and incubated with cells for 24 h, 48 h, and 72 h, respectively. CCK-8 reagent (Solerbo) was used to detect the proliferation of MC38 cells.
[0111] The results are as follows Figure 7 As shown, the strain A21038 and the commercial strain LGG can significantly inhibit the proliferation of colon cancer cells, and as time increases, the inhibitory effect of live bacteria becomes more significant (P<0.0001). The strain A21038 reaches a half-inhibitory effect at 72 hours after inactivation, which is significantly weaker than the effect of live bacteria. Therefore, it is speculated that the potential anti-colon cancer cell growth ability of the strain A21038 may mainly depend on the live bacteria themselves or the metabolites they produce, and the effect of the inactivated bacterial cells is weaker.
[0112] Embodiment 11
[0113] Inhibitory effect of fermented Lactobacillus mucilaginosus strain A21038 on mouse melanoma B16 cells
[0114] B16 cell line was inoculated and cultured in DMEM medium (TransGen) containing 10% fetal bovine serum. When the cells grew to the logarithmic phase, they were digested with trypsin and counted using a hemacytometer. The cells were evenly inoculated in a 96-well plate at 5,000 cells per well and cultured in a 37°C tri-gas incubator overnight.
[0115] The strain A21038 and the control strain LGG were taken out from the glycerol storage tube, streaked on the MRS solid plate, and cultured in a 37°C incubator. After 24 hours, a single clone was picked and cultured in 2 ml of MRS liquid culture medium for 12 to 16 hours. This step was repeated once to fully activate the strain and obtain a bacterial suspension. The OD of the bacterial suspension was adjusted. 600 to 0.5 (concentration is 1×10 6 CFU / mL), washed three times with PBS, and then divided into live bacteria and inactivated bacteria (70℃30min), and 0.2mL of bacterial suspension was added to each well of 96-well plate and incubated with cells for 24h. CCK-8 reagent (Solabo) was used to detect cell proliferation.
[0116] The results are as follows Figure 8 As shown in the results, the strain A21038 can significantly inhibit the proliferation of melanoma cells (P<0.0001), and its effect is comparable to that of the control strain LGG. Whether it is A21038 or the commercial strain LGG, the effect after inactivation is weaker than that of live bacteria. Therefore, it is speculated that the potential anti-melanoma cell growth ability of the strain A21038 may be dependent on the live bacteria themselves or the metabolites produced by them, and the effect of the bacterial cells after inactivation is weaker.
[0117] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of fermented Lactobacillus fermentum in the preparation of products with at least two of the following functions: anti-oxidation, anti-aging, anti-bacterial and anti-tumor.
2. The application according to claim 1, characterized in that: The antioxidant is manifested in the ability to scavenge at least one of the following: DPPH free radical, hydroxyl free radical, superoxide anion and H2O2.
3. The application according to claim 1, characterized in that: The anti-aging effect is manifested in having superoxide dismutase activity and / or glutathione peroxidase activity.
4. The use according to any one of claims 1 to 3, characterized in that: When preparing an anti-oxidation and / or anti-aging product, the product comprises at least one of the following: medicine, health care product, cosmetic and food.
5. The use according to claim 1, characterized in that: The bacteria in the antibacterial property include Escherichia coli.
6. The use according to claim 1, characterized in that: The anti-tumor tumor or cancer includes colon cancer and / or melanoma.
7. The use according to any one of claims 1, 5 and 6, characterized in that: When the antibacterial and / or anti-tumor product is prepared, the product includes a medicine.
8. A fermentative Lactobacillus mucilaginosus strain A21038, characterized in that: The deposit number is GDMCC No:64675.
9. A probiotic, characterized in that: The active ingredient comprises the fermented Lactobacillus mucilaginosus strain A21038 as claimed in claim 8.
10. Use of the fermented Lactobacillus mucilaginosus strain A21038 according to claim 8 or the probiotic according to claim 9 in the preparation of a product having at least one of antioxidant, anti-aging, antibacterial and anti-tumor properties.
Citation Information
Patent Citations
Lactobacillus fermentum strain A21196 with 5-hydroxytryptamine secretion function and application of lactobacillus fermentum strain A21196
CN116004455A
Lactobacillus mucilaginosus VB216 and application thereof
CN116656578A
Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor food drugs
CN117402768A
Lactobacillus mucilaginosus KS6 and application of lactobacillus mucilaginosus KS6 in preparation of anti-inflammatory and sleep-aiding foods and medicines
CN117721033A
Polymer compositions
WO2019023555A1
Cited By
Lactobacillus mucilaginosus BL-SWN1 and application thereof
CN120272367A
Lactobacillus mucilaginosus 121 with anti-oxidation effect and application of lactobacillus mucilaginosus 121
CN121555380A
Lactobacillus muciidus 121 with antioxidant effect and application thereof
CN121555380B
Fermented lactobacillus rimosii and application thereof in anti-aging
CN122081153A
